NASDAQ:FEMY Femasys 3/31/2026 Earnings Report $0.39 +0.01 (+1.95%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$0.38 -0.01 (-1.81%) As of 05/29/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Femasys EPS ResultsActual EPS-$0.01Consensus EPS -$0.08Beat/MissBeat by +$0.07One Year Ago EPSN/AFemasys Revenue ResultsActual Revenue$0.81 millionExpected Revenue$1.06 millionBeat/MissMissed by -$246.61 thousandYoY Revenue GrowthN/AFemasys Announcement DetailsQuarterDate3/31/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsFemasys' next earnings date is estimated for Wednesday, August 12, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Femasys Earnings HeadlinesFemasys (FEMY) Stock Forecast & Price TargetMay 19, 2026 | investing.comFemasys Amends Financing Terms and Issues New WarrantsMay 19, 2026 | theglobeandmail.comTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, changes behind the scenes may be opening the door to new cash-flow opportunities designed to generate regular monthly income — without requiring investors to pick individual stocks or predict market direction. In a new briefing, he explains how the structure works and what investors should understand before considering it.May 30 at 1:00 AM | Investors Alley (Ad)Femasys updates corporate presentation on women’s health portfolioMay 13, 2026 | tipranks.comFemasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ CatheterMay 13, 2026 | globenewswire.comFemasys Inc.: Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate UpdateMay 9, 2026 | finanznachrichten.deSee More Femasys Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email. Email Address About FemasysFemasys (NASDAQ:FEMY) International, Inc. is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care. The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography. This system is intended to facilitate earlier and more accurate diagnosis of intrauterine abnormalities such as polyps, fibroids and adhesions. Femasys is also developing a pipeline of complementary devices aimed at expanding its portfolio of interventional gynecological tools. Femasys is listed on the Nasdaq under the ticker symbol FEMY and is incorporated in Delaware with principal executive offices in Beijing, China. The company’s leadership team includes medical device veterans with deep experience in product development, regulatory affairs and commercial strategy. Femasys continues to pursue regulatory clearances in key markets, including CE marking in Europe, while exploring opportunities to introduce its technologies across Asia, North America and other regions.View Femasys ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 05/25 - 05/29Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%Costco’s Strong Quarter Still Leaves Investors With a Valuation ProblemMongoDB's AI Advantage Is Starting to Show Up in ResultsShares Fall, Targets Rise—Markets and Analysts Diverge on SynopsysDollar Tree Keeps Winning After Family Dollar DivorceSalesforce Stock Finds Support as AI Momentum Builds Upcoming Earnings Hewlett Packard Enterprise (6/1/2026)Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
